Physician

Brian Kent Ulrich, M.D.

According to 2025 Medicare claims, Brian Ulrich, M.D. (NPI: 1811975063) practices medical oncology in the Wichita Falls, TX market, with the plurality of this provider's patient population coming from Wichita, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1811944101; TIN: 752131429) and primary practice location at 76310-1610. Ulrich is affiliated with the Lifecare ACO LLC (ACO ID: A3644), Caravan Health ACO 43 LLC (ACO ID: A4974), and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Ulrich's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 948 traditional Medicare patients, billed 279,144 HCPCS/CPT codes, and received $3,453,935 in Medicare payments. The top billing code was 99213 (Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more). Part D data shows 520 prescription claims across 87 beneficiaries totaling $743,169 in drug costs, led by Bosulif (Bosutinib). DME data shows 12 claims. Open Payments data shows 42 records totaling $264,645. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $655,261 to $3,453,935. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $450,035 and ending at $743,169. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $4,309 and ending at $1,067.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	516	106,267	$655,261
2016	988	178,658	$1,060,890
2017	1,222	200,845	$1,987,910
2018	1,120	310,830	$2,707,933
2019	1,131	366,266	$2,613,042
2020	1,053	334,301	$2,510,391
2021	980	335,644	$2,336,715
2022	980	417,119	$2,834,699
2023	944	389,432	$3,312,419
2024	948	279,144	$3,453,935

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	84	462	$450,035
2016	144	791	$931,201
2017	130	837	$886,450
2018	120	673	$827,076
2019	108	634	$649,460
2020	109	627	$980,807
2021	108	540	$653,991
2022	113	534	$510,863
2023	84	506	$337,769
2024	87	520	$743,169

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	32	$838
2016	N/R	35	$2,370
2017	N/R	32	$1,206
2018	N/R	16	$827
2019	N/R	34	$1,044
2020	N/R	12	$311
2021	N/R	13	$1,132
2022	N/R	61	$3,150
2023	N/R	14	$4,533
2024	N/R	12	$276

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	273	564	$59
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	227	393	$44
80053	Blood test, comprehensive group of blood chemicals	226	507	$10
36415	Insertion of needle into vein for collection of blood sample	296	798	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	285	777	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Bosulif	Bosutinib	11	330	$55,469
Gammagard Liquid	Immun Glob G(Igg)/Gly/Iga Ov50	13	364	$55,379
Eliquis	Apixaban	51	1,589	$30,020
Imatinib Mesylate	Imatinib Mesylate	13	390	$19,430
Abiraterone Acetate	Abiraterone Acetate	21	630	$2,963

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	12	$276

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	20	$479	Boehringer Ingelheim Pharmaceuticals, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	22	$264,167	Janssen Research & Development, LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Brian Kent Ulrich, M.D.?

Tedicare shows public-source Medicare data for Brian Kent Ulrich, M.D. (NPI 1811975063), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Brian Kent Ulrich, M.D. have ACO affiliation data?

Brian Kent Ulrich, M.D. is shown with ACO affiliation data for Lifecare ACO LLC (MSSP, ACO ID A3644), Caravan Health ACO 43 LLC (MSSP, ACO ID A4974), and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Brian Kent Ulrich, M.D.?

Brian Kent Ulrich, M.D. is linked to TEXAS ONCOLOGY PA (billing NPI 1811944101) in the available physician profile data.

Does Brian Kent Ulrich, M.D. have Open Payments data?

Brian Kent Ulrich, M.D. has 42 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.